EN
DE
Over Harry Dolstra
Harry Dolstra was born in Smallingerland, the Netherlands and studied Biology at the University in Utrecht where he obtained his Master’s degree in 1993 in molecular biology and cellular immunology. He obtained his PhD degree (cum laude) in 1999 from the Faculty of Medical Sciences of the University of Nijmegen, whereupon he completed his post-doctorate work at the Radboud university medical center and the Institute for Immunology and Immunotherapy at University of Birmingham, UK. In 2003, he finished his tenure and started his own research group as assistant professor and became immunologist at the Cell therapy processing facility of the Laboratory for Hematology of the Department of Laboratory Medicine, Radboud university medical center. Here, he established his translational research program exploiting stem cell transplantation and cellular immunotherapy to fight cancer. In 2015, Harry Dolstra became associate professor in Translational Immunohematology, in 2017 director of the Cell therapy processing facility, and in 2023 full professor in Translational Immunohematology at the Radboud University. His contributions to science have been recognized with numerous awards and international lectures, including the Herman Boerhaave award in the field of Hematology (2000), Leukemia research awards from the Bekales foundation (2000, 2004), Radboud Principal Investigator awards (2009, 2014, 2017, 2020, 2023), Translational adult stem cell award (2009) and George Santos award for best clinical article for which I was senior author from the American Society for Blood and Marrow Transplantation (2014).
Functie(s)
- hoogleraar
Opleiding
- Post-doc, Radboudumc (Nijmegen, the Nederlands) & CRC Institute for Cancer Studies (Birmingham, UK)
- PhD Medical Sciences (cum laude), Radboudumc (Nijmegen, the Netherlands)
- Msc. Biology, University of Utrecht (Utrecht, the Netherlands)
Onderscheidingen
- KiKa grant 489: CAR-NK cells against acute myeloid leukemia
- KWF grant 15749: Proof-of-concept CAR-NK against ovarian carcinoma
- Radboud Oncology Fund: Next-Gen CART against multiple myeloma
Onderscheidingen
- KiKa grant 489: CAR-NK cells against acute myeloid leukemia
- KWF grant 15749: Proof-of-concept CAR-NK against ovarian carcinoma
- Radboud Oncology Fund: Next-Gen CART against multiple myeloma
- KWF DARE-NL Infrastructure grant Cell & Gene therapy
- KWF grant 13535: CAR-NK cells against ovarian cancer
- KWF grant 11564: NK4AML clinical trial
- KWF grant 10100: NK4EOC clinical trial
Researchfunctie
- full professor
